Julianne Smith

Title: Julianne Smith: Innovator in Engineered Immune Cells

Introduction

Julianne Smith is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of immunotherapy, particularly in the development of engineered immune cells. With a total of 2 patents, her work focuses on advancing cancer treatment options.

Latest Patents

Julianne's latest patents include the "Universal anti-CD22 chimeric antigen receptor engineered immune cells." This invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene. These engineered immune cells are designed to redirect immune cell specificity and reactivity toward selected tumor cells. They are particularly suited for treating relapsed refractory CD22 expressing cancers.

Career Highlights

Throughout her career, Julianne has worked with notable companies such as Cellectis S.A. and Cellectis. Her innovative approach and dedication to research have positioned her as a key figure in the field of cancer immunotherapy.

Collaborations

Julianne has collaborated with esteemed colleagues, including Murielle Derrien and Philippe Duchateau. These partnerships have further enhanced her research and development efforts in engineered immune cell technology.

Conclusion

Julianne Smith's contributions to the field of immunotherapy through her patented inventions demonstrate her commitment to advancing cancer treatment. Her work continues to inspire innovation in the medical community.